Only three cycles of nivolumab showed remarkable durable response and reversible myeloradiculoneuropathy in a patient with metastatic papillary renal cell carcinoma type 2.
Kazunori IwasakiToshitaka ShinToru InoueTadamasa ShibuyaKenichi HiraiTadasuke AndoHiromitsu MimataPublished in: IJU case reports (2021)
Nivolumab may be a promising treatment option for non-clear cell renal cell carcinoma such as papillary renal cell carcinoma.